The frontier of longevity science

How far can
human life
be extended?

We track the science attempting to slow ageing, repair biological damage and extend healthy human life.

Explore the evidence ↗What changed recently?

INDEPENDENT THINKINGEVIDENCE BEFORE HYPE

Optimistic about the possibilities. Exacting about the proof.17 evidence dossiers11 research briefings

My Ethernia

Build your longevity watchlist.

Follow the science that matters to you and see what changed since your last visit.

Open My Ethernia →

Latest Research

Longevity research — latest

All research briefings →

2026-09-03 · Frontier research

An animal organ becomes a bridge to a human transplant.

A first-in-human report described porcine kidney transplantation followed later by a human transplant.

Finding & interpretation

Study type: Human case study
Showed: One recipient spent 271 days free from dialysis with the pig kidney before declining graft function led to removal.
Did not show: Durable replacement for all recipients, freedom from immunosuppression, or whole-body rejuvenation.
Why it matters: Organ replacement could address a specific cause of death even while systemic ageing continues.
Ethernia interpretation: A concrete clinical milestone with a limited denominator. Watch graft durability, rejection, infection and replication; do not equate time off dialysis with added lifespan.
Evidence classification: Frontier

Original source ↗

2026-06-09 · Rejuvenation

Reprogramming reaches a first-patient milestone.

The sponsor reported the first patient dosed in the ER-100 eye study.

Finding & interpretation

Study type: Sponsor announcement
Showed: A human safety study began dosing; this announcement contained no efficacy result.
Did not show: Restored vision, systemic age reversal or longer life.
Why it matters: Controlled delivery is one of the central barriers between a cellular idea and a therapy.
Ethernia interpretation: The next meaningful evidence is a safety and outcome report, not the number of headlines about the first dose.
Evidence classification: Frontier

Original source ↗

2026-05-30 · Frontier research

Cancer detection advances—and misses its primary test.

GRAIL presented NHS-Galleri results at ASCO.

Finding & interpretation

Study type: Sponsor report / conference results
Showed: The trial missed its primary endpoint; the sponsor also reported favourable stage-IV findings.
Did not show: A demonstrated cancer-mortality reduction.
Why it matters: Early detection needs outcome evidence: finding more cancers and preventing deaths are not interchangeable.
Ethernia interpretation: Read the endpoint hierarchy before adopting the headline. Secondary signals can guide follow-up without converting a missed primary endpoint into a successful trial.
Evidence classification: Frontier

Original source ↗

Discovery feed

New studies

All latest research →

Automatically collected research · Not yet reviewed by Ethernia. Topic tags describe title keywords, not evidence strength. Listings may include reviews and animal or laboratory studies.

Last checked: 2026-10-31T22:45:04+00:00

Longevity drugs